This month’s small-cap candidate is Endologix (ELGX), a developer of devices for the treatment of abdominal aortic aneurysms, a condition that affects 1.2 million Americans. Because the company’s revolutionary endovascular aneurysm repair surgery is far less invasive than open surgery, it is fast becoming the dominant treatment. With its strong products and pipeline, I believe Endologix can grow sales at a compound rate of 50% over the next two years. The stock gained 76% in 2011, and throughout the rally, the stock was supported by its 50-day moving average. Since 2012, the stock has traded in a range but now appears ready to rebound higher. Open up your issue now and read all the details on Endologix and all my current stock recommendations.
